Over the next fourteen years Brånemark published many studies on the use of titanium in dental implantology until in 1978 he entered into a commercial partnership with the Swedish defense company, Bofors AB for the development and marketing of his dental implants. With Bofors (later to become Nobel Industries) as the parent company, Nobelpharma AB (later to be renamed Nobel Biocare) was founded in 1981 to focus on dental implantology. To the present day over 7 million Brånemark System implants have now been placed and hundreds of other companies produce dental implants. All dental implants currently available are axilly symmetric (cylindrical form) and do not fit precisely in the individual tooth socket. For this reason additional risky and costly interventions are regularly required to fill the gaps between the implant and bone.

The latest development in immediate dental implantology are root analogue Zirconia implants, which fit exactly into the extraction socket, rendering additional procedures such as bone transplantation or implantation of bone substitute as well as drilling absolutely unnecessary.
Success rates
Dental implant success is related to operator skill, quality and quantity of the bone available at the site, and also to the patient's oral hygiene. Various studies have found the 10 year success rate of implants to be between 90 and 95%. Patients who smoke experience significantly poorer success rates.